Biogen Inc. (BIIB)

227.06
NASDAQ : Health Technology
Prev Close 229.11
Day Low/High 225.82 / 230.51
52 Wk Low/High 216.12 / 388.67
Avg Volume 2.48M
Exchange NASDAQ
Shares Outstanding 193.89M
Market Cap 44.42B
EPS 21.60
P/E Ratio 9.88
Div & Yield N.A. (N.A)
Biogen's Big Alzheimer's Presentation on Wednesday: What You Need to Know

Biogen's Big Alzheimer's Presentation on Wednesday: What You Need to Know

The biotech giant will present detailed results of its mid-stage trials of BAN2401 at the Alzheimer's Association International Conference in Chicago.

Jim Cramer: We've Got an Extremist Market

Jim Cramer: We've Got an Extremist Market

Don't buy up when there's nothing but rampant pin action.

Dow Breaks 3-Day Skid; Nasdaq Rebounds to End Flat

Dow Breaks 3-Day Skid; Nasdaq Rebounds to End Flat

The Dow ended higher, breaking a 3-day skid, while the Nasdaq rebounded to end little changed after hitting a record high earlier.

Biogen Jumps on Earnings Beat Ahead of Alzheimer's Presentation

Biogen Jumps on Earnings Beat Ahead of Alzheimer's Presentation

The biotech giant also raised its 2018 guidance for both revenue and earnings.

Alphabet, AT&T, Verizon and New York Daily News - 5 Things You Must Know

Alphabet, AT&T, Verizon and New York Daily News - 5 Things You Must Know

U.S. stock futures rise on Tuesday, with solid corporate earnings boosting shares on Wall Street; Alphabet is set to open at a record high after the parent of Google posts a significant earnings beat; AT&T and Verizon highlight Tuesday's earnings calendar.

3 Things to Watch When Biogen Reports Second-Quarter Results

3 Things to Watch When Biogen Reports Second-Quarter Results

The Cambridge, Mass.-based biotech is scheduled to unveil its second-quarter results before the market open on July 24.

Prepare for Volatility Around Biogen Ahead of Alzheimer's Presentation: Leerink

Prepare for Volatility Around Biogen Ahead of Alzheimer's Presentation: Leerink

Positive readings from the biotech giant's Alzheimer's drug could drive the stock to as high as $393.

Target, US Bancorp, BlackRock: 'Mad Money' Lightning Round

Target, US Bancorp, BlackRock: 'Mad Money' Lightning Round

Jim Cramer is bullish on Target, Biogen Idec, Regions Financial, Lockheed Martin, US Bancorp, BlackRock and more.

Market Loves Fintech: Cramer's 'Mad Money' Recap (Thursday 7/19/18)

Market Loves Fintech: Cramer's 'Mad Money' Recap (Thursday 7/19/18)

Jim Cramer says financial payment companies are the most beloved in the market right now. He explains digitized payment companies. And love.

5 Big Biotech Stories to Watch

5 Big Biotech Stories to Watch

The biotech and pharmaceutical industries have had some big news in recent weeks. Here's what you should know to stay up-to-date.

2 Small Biotechs I Like in the Second Half

2 Small Biotechs I Like in the Second Half

Adamis Pharmaceuticals and Pieris Pharmaceuticals are names to watch.

Biogen Stock: A Long-Term Bullish Perspective

Biogen Stock: A Long-Term Bullish Perspective

After Friday's surge another look at BIIB is warranted.

Jim Cramer: The Strength in Pharma, Health Care and Real Estate Is Transient

Jim Cramer: The Strength in Pharma, Health Care and Real Estate Is Transient

The seemingly terrific rationales for strength in these economically sensitive sectors seem glib until the bigger global economic issues get resolved.

Biogen Sparks Hope on Treating Alzheimer's Disease: Everything You Must Know

Biogen Sparks Hope on Treating Alzheimer's Disease: Everything You Must Know

Biogen delivered promising results on a new Alzheimer's disease treatment. And investors rewarded the company accordingly.

Stocks Rise Despite Trade War Worries; Biogen Shares Soar -- ICYMI

Stocks Rise Despite Trade War Worries; Biogen Shares Soar -- ICYMI

Here's what you need to know now for Friday, July 6.

Video: Jim Cramer on the Jobs Report, Tariffs and Biogen

Video: Jim Cramer on the Jobs Report, Tariffs and Biogen

TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer weighs in on Friday's trending market topics from the floor of the New York Stock Exchange.

Biogen, Eisai Aim to Bring Their Alzheimer Drug to Market

Biogen, Eisai Aim to Bring Their Alzheimer Drug to Market

Real Money reveals the crucial component Biogen got right in this trial and what it plans for the drug next.

Biogen Shares Soar on Positive Alzheimer's Drug Results

Biogen Shares Soar on Positive Alzheimer's Drug Results

The company's drug showed promising results versus a placebo in a Phase 2 trial.

Biogen Wins a Battle, Not the War Against Alzheimer's

Biogen Wins a Battle, Not the War Against Alzheimer's

The history of trying to cure Alzheimer's is full of mistakes and false promises.

3 Must Reads on the Market From TheStreet's Top Columnists

3 Must Reads on the Market From TheStreet's Top Columnists

Jim Cramer and our other experts discuss bulls and bears, Biogen, and 4 bargain stocks.

Biotech Stocks Rally on Biogen's Landmark Test

Biotech Stocks Rally on Biogen's Landmark Test

Investors might be finally recognizing the hidden value of the firms' drug research and development.

Biogen: Let the Situation Cool Off a Bit Before Buying

Biogen: Let the Situation Cool Off a Bit Before Buying

There are issues in the study that are keeping some buyers cautious and causing selling into the early strength.

Biogen Rebounds 25% in 2 Months Since TheStreet Ratings Buy Recommendation

Biogen Rebounds 25% in 2 Months Since TheStreet Ratings Buy Recommendation

Since TheStreet Ratings upgrade on May 1, shares of the biotech giant have recovered strongly.

Gilead Sciences Is Displaying a Bullish Long-Term Pattern

Gilead Sciences Is Displaying a Bullish Long-Term Pattern

This biotech's weekly chart is very encouraging.

Exposure to Feverish Biogen Should Give These 2 Biotech ETFs Booster Shots

Exposure to Feverish Biogen Should Give These 2 Biotech ETFs Booster Shots

First Trust NYSE Arca Biotechnology Index Fund and iShares Nasdaq Biotechnology ETF look like two ways to catch the rally in Biogen.

Biogen Soars, and It May Signal a Breakout Gap to Further Gains

Biogen Soars, and It May Signal a Breakout Gap to Further Gains

My longer-term price target is now $416.

Sarepta Shares Skyrocket on Early Results for DMD Gene Therapy

Sarepta Shares Skyrocket on Early Results for DMD Gene Therapy

The Duchenne Muscular Dystrophy specialist announces early results that show a gene-based treatment for the debilitating disease may be just two years away.

Biogen Can Do More For the Bulls

Biogen Can Do More For the Bulls

Charts suggest that shares of Biogen have farther to run.

Emboldened By Biotech Names

Emboldened By Biotech Names

For the trade, I'm opting to use the iShares Nasdaq Biotechnology ETF.

TheStreet Quant Rating: C (Hold)